title: N-Heterocyclic Carbene Capture by Cytochrome P450 3A4.
abstract: Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved in human drug metabolism, and its inhibition may result in adverse interactions or, conversely, favorably reduce the systemic elimination rates of poorly bioavailable drugs. Herein we describe a spectroscopic investigation of the interaction of CYP3A4 with N-methylritonavir, an analog of ritonavir, widely used as a pharmacoenhancer. In contrast to ritonavir, the binding affinity of N-methylritonavir for CYP3A4 is pH-dependent. At pH <7.4, the spectra are definitively type I, whereas at pH ≥7.4 the spectra have split Soret bands, including a red-shifted component characteristic of a P450-carbene complex. Variable-pH UV-visible spectroscopy binding studies with molecular fragments narrows the source of this pH dependence to its N-methylthiazolium fragment. The C2 proton of this group is acidic, and variable-pH resonance Raman spectroscopy tentatively assigns it a pKa of 7.4. Hence, this fragment of N-methylritonavir is expected to be readily deprotonated under physiologic conditions to yield a thiazol-2-ylidene, which is an N-heterocyclic carbene that has high-affinity for and is presumed to be subsequently captured by the heme iron. This mechanism is supported by time-dependent density functional theory with an active site model that accurately reproduces distinguishing features of the experimental UV-visible spectra of N-methylritonavir bound to CYP3A4. Finally, density functional theory calculations support that this novel interaction is as strong as the tightest-binding azaheterocycles found in P450 inhibitors and could offer new avenues for inhibitor development.
authors.affiliation: Department of Physiology and Biophysics and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
authors.forename: Gareth K
authors.initials: GK
authors.lastname: Jennings
authors.affiliation: Department of Physiology and Biophysics and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Ritchie
authors.affiliation: Department of Physiology and Biophysics and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
authors.forename: Lisa S
authors.initials: LS
authors.lastname: Shock
authors.affiliation: Department of Physiology and Biophysics and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia.
authors.forename: Charles E
authors.initials: CE
authors.lastname: Lyons
authors.affiliation: Department of Physiology and Biophysics and the Massey Cancer Center, Virginia Commonwealth University School of Medicine, Richmond, Virginia john.hackett@vcuhealth.org.
authors.forename: John C
authors.initials: JC
authors.lastname: Hackett
mesh_terms: D051544:Cytochrome P-450 CYP3A / Q000737:chemistry / Q000378:metabolism*; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000737:chemistry* / Q000494:pharmacology; D006571:Heterocyclic Compounds / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008024:Ligands; D008697:Methane / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D008958:Models, Molecular; D011522:Protons; D011789:Quantum Theory; D019438:Ritonavir / Q000737:chemistry / Q000494:pharmacology; D013056:Spectrophotometry, Ultraviolet; D013059:Spectrum Analysis, Raman; D017186:Titrimetry
chemical_list: D065692:Cytochrome P-450 CYP3A Inhibitors; D006571:Heterocyclic Compounds; D008024:Ligands; D011522:Protons; C030011:carbene; D051544:Cytochrome P-450 CYP3A; D019438:Ritonavir; D008697:Methane